ClinicalTrials.gg
CompletedNCT02475109Updated Sep 28, 2016

Study of Topical Ocular PAN-90806 in PDR

A Phase 1 interventional study of PAN-90806 Ophthalmic Solution in Diabetic Retinopathy, sponsored by PanOptica, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-28.

Sponsored by PanOptica, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 55 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Enrollment
171st of 196
10 · median 72
Started
2015
with 10 others
Phase 1
29 of 267
4 open now
Registered
108th of 267
by date

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 171st largest by enrollment of the 196 interventional ones that give a count, is one of 11 that started in 2015, is one of 29 in phase 1, and was the 108th registered.

Diabetic Retinopathy

779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to assess the safety and tolerability of topical ocular PAN-90806 in patients with proliferative diabetic retinopathy.

03

Conditions studied

  • Diabetic Retinopathy

Browse trials for

Keywords

  • Proliferative Diabetic Retinopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older with type 1 or type 2 diabetes
  • Proliferative diabetic retinopathy (PDR) in study eye retina with or without diabetic macular edema (DME) involving the center of the macula
  • Demonstrate the ability, or have a family member who is willing and able, to instill topical ocular drops in the study eye

Exclusion criteria

Exclusion Criteria:

  • Current or recent use (within the last 3 months) of anti-vascular endothelial growth factors (anti-VEGF) in either eye;
  • Uncontrolled hypertension despite use of antihypertensive medications
  • Unwillingness to refrain from wearing contact lenses for the duration of the study.
  • Participation in any drug or device study, systemic or ocular, within past 3 months
  • Women who are pregnant or nursing
  • Known serious allergies or to the fluorescein dye used in angiography or to the components of the PAN-90806 formulation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    PAN-90806 Ophthalmic Solution

    PAN-90806 Ophthalmic Solution taken daily for 8 weeks.

    Drug: PAN-90806 Ophthalmic Solution

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Patients with Adverse Events

    Safety will be assessed based upon the incidence of all adverse events, ocular and systemic

    Time frame: 2 months

Secondary outcomes

  1. The mean change in best-corrected visual acuity from baseline

    Time frame: Week 8

  2. Change in preretinal neovascularization

    descriptive observations of the presence and extent as determined by ultra-wide field fluorescein angiography (FA) and color fundus photography (FP)

    Time frame: Week 4 and Week 8

  3. The mean number of rescue treatments during the study

    Time frame: Week 8

  4. Time to first rescue treatment

    Time frame: up to Week 8

07

Study locations

2 sites
  • Valley Retina Institute
    Harlingen, Texas 78550, United States
  • Valley Retina Institute
    McAllen, Texas 78503, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2015, a primary completion of May 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2015
First posted
Jun 18, 2015
Start
Aug 2015
Primary completionActual
May 2016
CompletionActual
Jul 2016
Last update
Sep 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02475109
Lead sponsor
PanOptica, Inc.
Responsible party
Sponsor
First posted
Jun 18, 2015
Start date
Aug 2015
Primary completion
May 2016
Completion
Jul 2016
Last update
Sep 28, 2016

Study contacts

Victor H Gonzalez, M.D.
principal investigator · Valley Retina Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cp-547632

Start the discussion